[ET Net News Agency, 26 February 2020] CSPC Pharmaceutical Group Limited (01093) said
the "Montelukast Sodium Tablets (10mg)" and "Montelukast Sodium Chewable Tablets (4mg,
5mg)" developed by CSPC Ouyi Pharmaceutical Co., Ltd., a subsidiary of the company, has
been granted drug registration approval by the National Medical Products Administration of
the People's Republic of China, being the second product of this type deemed as passing
the consistency of quality and efficacy evaluation of generic drugs in China.
Montelukast sodium is an oral preparation that can notably improve symptoms of asthma
and allergic rhinitis. It is used for the prevention and long-term treatment of asthma,
including prevention of daytime and nighttime symptoms of asthma, treatment of asthma in
aspirin-sensitive patients and prevention of exercise-induced bronchoconstriction; and
also used for seasonal and perennial allergic rhinitis. (RC)